Compare ARK Genomic Revolution ETF (ARKG) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs F5 Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while F5 Inc trades at $428.2 (market cap $24.28B). The key difference: F5 Inc is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | FFIV | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $430.39 |
52-Week Low | $23.09 | $223.99 |
Market Cap | — | $24.28B |
Enterprise Value | — | $23.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
F5 (FFIV) trades at $430.39, showing minimal daily movement with a 0.02% gain. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $3.09B in 2025. Technical indicators signal a bullish trend, with the price above key support levels. Recent strategic moves include AI security platform expansion and acquisitions, positioning the company for continued growth in the cybersecurity sector.
The outlook remains positive with strong earnings momentum and strategic AI investments, though valuation metrics appear elevated. Key risks include competitive pressures and execution challenges in new market segments. Analyst consensus leans cautious with a $397 price target below current levels, suggesting potential near-term consolidation despite long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
